Cargando…

Hepatitis C Virus Genotype 5 Variability in Treatment-Naïve Patients in South Africa

INTRODUCTION: Hepatitis C virus (HCV) genotype 5 was originally identified in South Africa, where it represents 35–60% of all HCV infections. There are limited data on resistance-associated variants (RAVs) in South Africa. Thus, we investigated variability within the NS3/NS4A, NS5A, and NS5B genes o...

Descripción completa

Detalles Bibliográficos
Autores principales: Maunye, Tshegofatso K., Gededzha, Maemu P., Blackard, Jason T., Rakgole, Johnny N., Selabe, Selokela G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353306/
https://www.ncbi.nlm.nih.gov/pubmed/37231989
http://dx.doi.org/10.1159/000528178
_version_ 1785074687372427264
author Maunye, Tshegofatso K.
Gededzha, Maemu P.
Blackard, Jason T.
Rakgole, Johnny N.
Selabe, Selokela G.
author_facet Maunye, Tshegofatso K.
Gededzha, Maemu P.
Blackard, Jason T.
Rakgole, Johnny N.
Selabe, Selokela G.
author_sort Maunye, Tshegofatso K.
collection PubMed
description INTRODUCTION: Hepatitis C virus (HCV) genotype 5 was originally identified in South Africa, where it represents 35–60% of all HCV infections. There are limited data on resistance-associated variants (RAVs) in South Africa. Thus, we investigated variability within the NS3/NS4A, NS5A, and NS5B genes of treatment-naïve individuals with HCV genotype 5 infection at the Dr. George Mukhari Academic Hospital (DGMAH) in Pretoria, South Africa. METHODS: Nested PCR was performed to amplify the NS3/4A, NS5A, and NS5B genes. RAVs were evaluated using the Geno2pheno tool. RESULTS: In the NS3/4A gene, F56S and T122A were detected in one sample each. The D168E mutation was detected in 7 samples. Within the NS5A gene, the T62M mutation was detected in 2 individuals. In the NS5B gene, 8 of 12 individuals (67%) had the A421V mutation, while all 12 individuals (100%) had the S486A mutation. DISCUSSION: RAVs were detected frequently among treatment-naïve individuals with HCV genotype 5 infection in South Africa. Thus, resistance testing may be prudent when initiating treatment of patients with genotype 5 infection. Additional population-based studies are needed to understand the prevalence of these RAVs during HCV genotype 5 infection.
format Online
Article
Text
id pubmed-10353306
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-103533062023-07-19 Hepatitis C Virus Genotype 5 Variability in Treatment-Naïve Patients in South Africa Maunye, Tshegofatso K. Gededzha, Maemu P. Blackard, Jason T. Rakgole, Johnny N. Selabe, Selokela G. Intervirology Research Article INTRODUCTION: Hepatitis C virus (HCV) genotype 5 was originally identified in South Africa, where it represents 35–60% of all HCV infections. There are limited data on resistance-associated variants (RAVs) in South Africa. Thus, we investigated variability within the NS3/NS4A, NS5A, and NS5B genes of treatment-naïve individuals with HCV genotype 5 infection at the Dr. George Mukhari Academic Hospital (DGMAH) in Pretoria, South Africa. METHODS: Nested PCR was performed to amplify the NS3/4A, NS5A, and NS5B genes. RAVs were evaluated using the Geno2pheno tool. RESULTS: In the NS3/4A gene, F56S and T122A were detected in one sample each. The D168E mutation was detected in 7 samples. Within the NS5A gene, the T62M mutation was detected in 2 individuals. In the NS5B gene, 8 of 12 individuals (67%) had the A421V mutation, while all 12 individuals (100%) had the S486A mutation. DISCUSSION: RAVs were detected frequently among treatment-naïve individuals with HCV genotype 5 infection in South Africa. Thus, resistance testing may be prudent when initiating treatment of patients with genotype 5 infection. Additional population-based studies are needed to understand the prevalence of these RAVs during HCV genotype 5 infection. S. Karger AG 2023-05-09 /pmc/articles/PMC10353306/ /pubmed/37231989 http://dx.doi.org/10.1159/000528178 Text en © 2023 The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Research Article
Maunye, Tshegofatso K.
Gededzha, Maemu P.
Blackard, Jason T.
Rakgole, Johnny N.
Selabe, Selokela G.
Hepatitis C Virus Genotype 5 Variability in Treatment-Naïve Patients in South Africa
title Hepatitis C Virus Genotype 5 Variability in Treatment-Naïve Patients in South Africa
title_full Hepatitis C Virus Genotype 5 Variability in Treatment-Naïve Patients in South Africa
title_fullStr Hepatitis C Virus Genotype 5 Variability in Treatment-Naïve Patients in South Africa
title_full_unstemmed Hepatitis C Virus Genotype 5 Variability in Treatment-Naïve Patients in South Africa
title_short Hepatitis C Virus Genotype 5 Variability in Treatment-Naïve Patients in South Africa
title_sort hepatitis c virus genotype 5 variability in treatment-naïve patients in south africa
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353306/
https://www.ncbi.nlm.nih.gov/pubmed/37231989
http://dx.doi.org/10.1159/000528178
work_keys_str_mv AT maunyetshegofatsok hepatitiscvirusgenotype5variabilityintreatmentnaivepatientsinsouthafrica
AT gededzhamaemup hepatitiscvirusgenotype5variabilityintreatmentnaivepatientsinsouthafrica
AT blackardjasont hepatitiscvirusgenotype5variabilityintreatmentnaivepatientsinsouthafrica
AT rakgolejohnnyn hepatitiscvirusgenotype5variabilityintreatmentnaivepatientsinsouthafrica
AT selabeselokelag hepatitiscvirusgenotype5variabilityintreatmentnaivepatientsinsouthafrica